Recent Quotes (30 days)

You have no recent quotes
chg | %

AstraZeneca plc  

(Public, LON:AZN)   Watch this stock  
Find more results forAZN
+35.50 (0.69%)
Jul 21 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 5,058.00 - 5,236.67
52 week 3,996.00 - 5,520.00
Open 5,135.00
Vol / Avg. 0.00/1.82M
Mkt cap 65,076.36M*
P/E 24.99
Div/yield 150.20*
EPS 2.06*
Shares 1,265.78M
Beta     -
Inst. own     -
Jul 31, 2017
AstraZeneca PLC Investor Roadshow - Europe and North America Add to calendar
Jul 27, 2017
Q2 2017 AstraZeneca PLC Earnings Call - 1:30pm BST - Add to calendar
Jul 27, 2017
Q2 2017 AstraZeneca PLC Earnings Media Conference - 9:00am BST - Add to calendar
Jul 27, 2017
Q2 2017 AstraZeneca PLC Earnings Release - 7:00am BST - Add to calendar
Jun 22, 2017
AstraZeneca PLC at JPMorgan European Healthcare Conference
Jun 21, 2017
AstraZeneca PLC at Citi European Healthcare Conference
Jun 14, 2017
AstraZeneca PLC at Barclays European Select Conference
Jun 13, 2017
AstraZeneca PLC at Goldman Sachs Group Investor Conference
Jun 9, 2017
AstraZeneca PLC at Bryan Garnier Oncology Day
Jun 9, 2017
AstraZeneca PLC at Jefferies Healthcare Conference

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 9.47% 14.81%
Operating margin 16.97% 21.31%
EBITD margin - 30.92%
Return on average assets 3.33% 5.56%
Return on average equity 15.47% 20.99%
Employees 59,700 -
CDP Score - A


Cambridge Biomedical Campus 1 Francis Crick Avenue
United Kingdom - Map
+44-20-73045000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Officers and directors

Pascal Soriot Executive Director and Chief Executive Officer
Age: 57
Marc Dunoyer Executive Director, Chief Financial Officer
Age: 64
Fiona Cicconi Executive Vice-President, Human Resources
Sean Bohen M.D., Ph.D. Chief Medical Officer, Executive Vice President - Global Medicines Development
Pam P. Cheng Executive Vice President - Operations and Information Technology
Age: 45
Ruud Dobber Executive Vice President, North America
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Mark Mallon Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs Executive Vice-President, International West
Menelas Pangalos Executive Vice President - IMED Biotech Unit and Global Business Development
Leon Wang Executive Vice President - Asia Pacific